Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
XFOR Stock Chart & Stats
$3.91
-$0.07(-10.26%)
At close: 4:00 PM EST
$3.91
-$0.07(-10.26%)
Day’s Range― - ―
52-Week Range$1.35 - $26.84
Previous CloseN/A
Volume769.31K
Average Volume (3M)596.59K
Market Cap
$341.88M
Enterprise Value$102.93M
Total Cash (Recent Filing)$122.42M
Total Debt (Recent Filing)$77.36M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Mar 12, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding87,436,690
10 Day Avg. Volume780,275
30 Day Avg. Volume596,594
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)6.66
Price to Sales (P/S)57.69
P/FCF Ratio-1.12
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue3.03
Enterprise Value/Gross Profit3.64
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$9.67Price Target Upside147.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.13
Revenue Forecast (FY)$34.51M
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceAnalyst raises the 12-month price target to $5 per diluted share, reflecting confidence in the company's updated financial model and strategic changes.
Corporate RestructuringThe company executed a corporate restructuring to ensure long-term growth, including a major overhaul of the executive suite.
Financial StrategyThe company fortified its balance sheet with a secondary offering and a private placement, resulting in total gross proceeds of $240.3M, providing an operational runway well beyond the date when results of Study 4WARD could be released.
Bears Say
Financial Performance3Q25 GAAP net loss was wider than both the analyst's and consensus estimates.
Revenue DeclineTotal revenue of $1.8M was down 10% sequentially and below the analyst's and consensus estimates.
X4 Pharmaceuticals News
XFOR FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was $1.35 and its highest was $26.84 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
X4 Pharmaceuticals Inc’s market cap is $341.88M.
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is Mar 12, 2026 which is in 86 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on Nov 05, 2025. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.505 by -$0.185.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate is -0.26.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 87,436,690 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.505. Following the earnings report the stock price went down -10.579%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in XFOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (147.31% Upside)
$9.67 (147.31% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 129.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $250.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 35.6%
Last 30 Days ▲ 35.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.29%
12-Months-Change
Fundamentals
Return on Equity
-156.87%
Trailing 12-Months
Asset Growth
-8.20%
Trailing 12-Months
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
XFOR Stock 12 Month Forecast
Average Price Target
$9.67
▲(147.31% Upside)
Technical Analysis
Ownership Overview
8.14% Insiders
0.82% Mutual Funds
14.17% Other Institutional Investors
76.46% Public Companies and
Individual Investors